As pigs are trending towards heavier market weights, veterinarians and producers have a vested interest in Mycoplasma hyopneumoniae (M. hyo) vaccines protecting through the market age of pigs. The objective of this study was to determine if a commercially licensed one dose M. hyo vaccine (Ingelvac MycoFLEX~R, Boehringer Ingelheim Vetmedica, Inc) administeted at four days post-weaning was inferior to either Ingelvac MycoFLEX~R administered in two 1/2 doses administered at four days post-weaning and 21days later or a second commercially available one dose vaccine (RespiSure-ONE~R, Pfizer Animal Health) administered once during the suckling period. The margin of non-inferiority for average daily gain (ADG) difference of -0.03 lb/day (SD 0.18) was chosen for vaccinated treatment groups and -0.05 lb/day (SD 0.18) difference was chosen between all vaccinated groups and non-vaccinated control group (NVC). A superiority test was conducted if the 95% CI for the ADG difference between treatments was greaterthan zero.
展开▼
